Literature DB >> 8521559

Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery.

J T Grayston1, C C Kuo, A S Coulson, L A Campbell, R D Lawrence, M J Lee, E D Strandness, S P Wang.   

Abstract

BACKGROUND: Chlamydia pneumoniae has been demonstrated in atherosclerotic lesions of coronary arteries and aorta. A seroepidemiological study found C pneumoniae-specific antibody more frequently in persons with significant carotid artery wall thickening than in matched control subjects. METHODS AND
RESULTS: Fresh-frozen or formalin-fixed tissue obtained at carotid endarterectomy was examined by immunocytochemistry (ICC) and the polymerase chain reaction (PCR) for the presence of C pneumoniae. Five of five fresh-frozen and formalin-fixed carotid endarterectomy specimens were positive for C pneumoniae by ICC (three of five by PCR). A total of 56 archival formalin-fixed, paraffin-embedded carotid endarterectomy tissues from three hospitals were examined by ICC. Thirty-two were positive. Thirteen normal carotid artery tissue sections from six patients were negative for C pneumoniae.
CONCLUSIONS: C pneumoniae organisms are frequently found in the advanced carotid atherosclerotic lesions of persons undergoing endarterectomy. Although these findings do not establish causality for C pneumoniae in carotid artery atherosclerosis, they should stimulate investigation of a possible causal or pathogenic role for the organism in the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521559     DOI: 10.1161/01.cir.92.12.3397

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

Review 1.  Molecular diagnosis of Chlamydia pneumoniae infection.

Authors:  J Boman; C A Gaydos; T C Quinn
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Chlamydia pneumoniae in vitro and in vivo: a critical evaluation of in situ detection methods.

Authors:  A Meijer; P J Roholl; S K Gielis-Proper; Y F Meulenberg; J M Ossewaarde
Journal:  J Clin Pathol       Date:  2000-12       Impact factor: 3.411

Review 3.  Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies.

Authors:  D Taylor-Robinson; B J Thomas
Journal:  J Clin Pathol       Date:  1998-11       Impact factor: 3.411

Review 4.  Microorganisms in the aetiology of atherosclerosis.

Authors:  S A Morré; W Stooker; W K Lagrand; A J van den Brule; H W Niessen
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

Review 5.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis.

Authors:  L A Jackson; L A Campbell; R A Schmidt; C C Kuo; A L Cappuccio; M J Lee; J T Grayston
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

7.  Failure to detect Chlamydia pneumoniae by cell culture and polymerase chain reaction in major arteries of 93 patients with atherosclerosis.

Authors:  J Bishara; S Pitlik; A Kazakov; G Sahar; M Haddad; A Vojdani; S Rosenberg; Z Samra
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-09       Impact factor: 3.267

Review 8.  Chaperonin 60 unfolds its secrets of cellular communication.

Authors:  Maria Maguire; Anthony R M Coates; Brian Henderson
Journal:  Cell Stress Chaperones       Date:  2002-10       Impact factor: 3.667

9.  Heat-inactivated C. pneumoniae organisms are not atherogenic.

Authors:  Jyotika Sharma; Yuhong Niu; Jianbo Ge; Grant N Pierce; Guangming Zhong
Journal:  Mol Cell Biochem       Date:  2004-05       Impact factor: 3.396

10.  Chlamydophila pneumoniae PknD exhibits dual amino acid specificity and phosphorylates Cpn0712, a putative type III secretion YscD homolog.

Authors:  Dustin L Johnson; James B Mahony
Journal:  J Bacteriol       Date:  2007-08-31       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.